Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Gut microbiome offers new avenue for detecting colorectal cancer
  • News

Gut microbiome offers new avenue for detecting colorectal cancer

  • 2 November 2023
  • Janet Fricker
Gut microbiome offers new avenue for detecting colorectal cancer
Total
0
Shares
0
0
0
0
0

Significant variations in the gut microbiome can be identified between people who develop pre-cancerous colonic lesions and those who do not. The Dutch study, abstract OP118, presented at United European Gastroenterology (UEG) Week 2023, held in Copenhagen, October 14–17, showed that the diversity of the gut microbiome was decreased in patients who went on to develop colorectal lesions.

“The study identified that both pre-existing and future colorectal pathologies are associated with the gut microbiome,” says lead author Ranko Gacesa. “Our findings suggest that the microbiome could act as a valuable tool to improve existing tests, advancing early detection methods for pre-cancerous lesions and colorectal cancer.”

Typically, colorectal cancer (CRC), which represents the second leading cause of cancer related death, develops from pre-cancerous lesions within the gut. Removal of the lesions offers an effective strategy for preventing development of CRC. However, existing non-invasive detection methods, such as the faecal immunochemical test, produce high numbers of false-positive results, leading to unnecessary colonoscopies. While CRC has been associated with changes in gut microbiota, the link between the microbiome and pre-cancerous lesions has been underexplored, and it has been unclear whether gut microbes can predict future onset of CRC.

The current study is part of Lifelines, a multi-generational, prospective cohort study including 167,000 people from the northern Netherlands (comprising 10% of the area’s population), designed to unravel the aetiology of multifactorial diseases. For Lifelines, major data collection initiatives take place every five years (2010, 2015 and 2020 etc), with the Dutch Microbiome Project based around the 2015 data collection.

The Dutch Microbiome Project, a large-prospective population study, was intended to determine the precise composition and function of the intestinal microbiome for 8,208 individuals from a three-generational cohort comprising 2,756 families. All participants provided faecal samples, which were analysed with metagenomic shotgun sequencing to profile bacteria present in the gut, the quantities of different bacteria, and broad biochemical functions of the bacteria. The team then linked data from the Dutch Microbiome Project 2015 collection to a Dutch nationwide pathology database (PALGA), which holds information from histology and pathology labs throughout the Netherlands. “The link allowed us to identify which participants developed colorectal polyps or cancer before the microbiome data was collected versus which participants developed them after,” Gacesa, from University Medical Centre Groningen, tells Cancerworld.

Altogether investigators identified 214 individuals who had developed pre-cancerous colorectal lesions between 2000 and 2015 (prior to faecal sampling): 106 cases with low-grade dysplasia; 24 with high-grade dysplasia; 60 with serrated polyps; and 26 cases of CRC. A further 305 individuals were identified who developed lesions between 2015 and 2022 (after faecal sampling):, 149 low-grade dysplasia; 78 high-grade dysplasia; 52 serrated polyps and 26 cases of CRC. The team also identified 202 individuals with normal colonoscopy findings, who were used for comparison as controls.

Results showed that microbiome diversity was decreased in participants who developed colonic lesions following sampling (false discovery rate <0.05, equivalent to a P value ≤0.05).

Microbiome composition and function differed between participants with pre-existing compared with future lesions as well as between those with different types of lesions. CRC, high-grade dysplasia, low-grade dysplasia and serrated polyps were all significantly associated with the total composition of the microbiome.

Bacterial species from the family Lachospiracea, and the genera Roseburia and Eubacterium were linked to future development of lesions. Furthermore, biochemical products produced by bacteria found to be associated with the development of lesions included aerobactin (a virulence factor bacteria use to take up iron), methanogenesis (the process whereby bacteria use methane gas to grow), flavine (a chemical that plays an important role in many biological processes), lysine (an essential amino acid), and quenosine (a nucleotide specific to bacteria not found in animals or humans).

The microbiome composition had a moderate predictive power for future lesions and CRC (AUROC ~0.7, equivalent to 70% correct prediction).

“We found that the gut microbiome of study participants who developed (pre) cancerous colonic lesions in 2015–2022 is significantly different from general population, implying that the gut microbiota might be involved in the development of colorectal lesions and cancer,” write the authors.

The team found that the associations between the microbiome and pre-cancerous lesions were similar to those that had been observed for cancer, although the effect sizes were lower. “This implies that changes in the gut microbiome are the result of not just cancer, but also pre-cancerous pathologies,” says Gacesa.

“Our results suggest that gut bacteria might be used to enhance currently used diagnostics for detection of colorectal polyps, and that microbiome-modulating therapies might play a role in prevention of colorectal cancer,” he adds. One future possibility, he suggests, would be to add tests for CRC-associated bacteria to the faecal tests currently used to screen for CRC.

The team are currently looking to find strain-level differences in bacteria linked to the development of CRC. In a second line of research, they are also investigating the chemicals produced by gut bacteria in participants who develop colorectal pathologies. “This will further our understanding of what might be causing cancer development and is important for designing future tests for cancer risk, as detection of specific small molecules is simpler than detecting specific bacteria,” explains Gacesa.

Ultimately, the team hope to perform a clinical trial exploring how well microbiome tests perform in detecting pre-cancerous lesions, cancer, and inflammatory bowel disease.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • Colorectal cancer
  • colorectal polyps
  • Microbiome
  • non-invasive diagnosis
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • News

Machine learning improves accuracy of survival prediction

  • 2 November 2023
  • Janet Fricker
View Post
Next Article
  • Voices

A more excellent way: Integration of science, medicine and holistic practices in Oncology and Life

  • 2 November 2023
  • Alexandra Filipovic
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Yeva Margaryan
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Yeva Margaryan
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.